Cannabics Pharmaceuticals is dedicated to the development of Personalized Anti-Cancer treatments.

Our main focus is the development of novel therapies and biotechnological tools aimed to providing relief from diverse ailments and treat human malignancies. These advanced tools include novel delivery systems, personalized medicine diagnostics and therapies based on Cannabinoid compounds.

Cannabics scientific research is devoted to create tailored therapies for cancer patients, utilizing advanced High-throughput screening (HTS) diagnostics and personalized bioinformatics tools.

The Company’s principal product is Cannabics SR' a long acting oil capsule that provides a safe, effective and reliable administration of cannabis. Composed solely from food grade materials, Cannabics SR' 5-10mg delivers a steady level of beneficial effects for 4–8 hours.

Cannabics Pharmaceuticals Inc. is traded in the US OTC stock exchange, under the trade symbol: CNBX

June 6, 2016, Cannabics Pharmaceuticals has Filed a PCT Application, Covering a Novel Personalized Anti-Cancer Diagnostics System.

March 22, 2016, Cannabics Pharmaceuticals Announces Start of Clinical Study in Israel for Cancer Patients.